Carlsmed Income Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2024	FY 2023
Period Ending	Mar '25 Mar 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023
Revenue	32.27	27.17	13.78
Revenue Growth (YoY)	-	97.16%	-
Cost of Revenue	8.25	7.12	3.88
Gross Profit	24.02	20.05	9.9
Selling, General & Admin	34.33	29.87	21.1
Research & Development	14.2	14.3	7.4
Operating Expenses	48.53	44.17	28.49
Operating Income	-24.51	-24.12	-18.59
Interest Expense	-1.46	-1.32	-0.64
Interest & Investment Income	1.61	1.33	0.33
Other Non Operating Income (Expenses)	-0.18	-0.14	-
Pretax Income	-24.54	-24.26	-18.9
Net Income	-24.54	-24.26	-18.9
Preferred Dividends & Other Adjustments	1.18	0.59	-
Net Income to Common	-25.72	-24.85	-18.9
Shares Outstanding (Basic)	23	23	22
Shares Outstanding (Diluted)	23	23	22
Shares Change (YoY)	-	4.62%	-
EPS (Basic)	-1.11	-1.10	-0.87
EPS (Diluted)	-1.11	-1.10	-0.87
Free Cash Flow	-26.42	-25.65	-17.62
Free Cash Flow Per Share	-1.14	-1.13	-0.81
Gross Margin	74.44%	73.80%	71.88%
Operating Margin	-75.96%	-88.80%	-134.93%
Profit Margin	-79.69%	-91.47%	-137.16%
Free Cash Flow Margin	-81.88%	-94.41%	-127.85%
EBITDA	-24.37	-23.98	-18.46
EBITDA Margin	-75.51%	-88.26%	-133.94%
D&A For EBITDA	0.15	0.15	0.14
EBIT	-24.51	-24.12	-18.59
EBIT Margin	-75.96%	-88.80%	-134.93%

Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q